THE STATE OF STATE OF THE STATE SHOW

How To Beat ALL Long-Haulers
COVID Symptoms,in 6 Days!

Do You or Anyone You Know Still Suffer w/ Any of These Symptoms, Post-Covid

- Chronic fatigue
- Dizziness
- Can't Take Deep Breathes
- Low-grade fever
- Loss of Taste/ Loss of Smell
- Memory lapses
- Muscle pain/weakness
- Diarrhea
- Vomiting
- Concentration difficulties

- Sleep difficulties
- Mood disorders
- Headache
- Chest tightness/pain
- Heart palpitations
- Cognitive impairment
- Motor deficits
- Exercise intolerance
- New onset of diabetes
- New onset of hypertension





Do You or Anyone You Know Still Suffer w/ Any of These Symptoms, Post-Covid

"Its incidence is estimated between 35% (outpatients) (Tenforde et al. 2020) and 87% (inpatients) (Carfi et al. 2020) of all individuals experiencing SARS-CoV-2 infection. In addition, the duration of the symptoms is unpredictable (Yelin et al. 2020; Barker-Davies et al. 2020; Sawadogo et al. 2020); after six months, an average of 14 persistent symptoms is reported by subjects suffering from long-haul COVID (Carod Artal 2021)."





According to Geneticists in China, BATS Are NOT the Origin of Covid-19's Virus: 1/2020

Received: 17 January 2020

Accepted: 21 January 2020

DOI: 10.1002/jmv.25682

RESEARCH ARTICLE



Cross-species transmission of the newly identified coronavirus 2019-nCoV

Wei Ji¹ | Wei Wang² | Xiaofang Zhao³ | Junjie Zai⁴ | Xingguang Li⁵

¹Department of Microbiology, Peking University Health Science Center School of Basic Medical Sciences, Beijing, China

²Department of Spleen and Stomach Diseases, The First affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China


³Department of Science and Technology, Ruikang Hospital Affiliated to Guangxi

Abstract

The current outbreak of viral pneumonia in the city of Wuhan, China, was caused by a novel coronavirus designated 2019-nCoV by the World Health Organization, as determined by sequencing the viral RNA genome. Many initial patients were exposed to wildlife animals at the Huanan seafood wholesale market, where poultry, snake, bats, and other farm animals were also sold. To investigate possible virus


















Codon usage bias

Sujatha Thankeswaran Parvathy 1, Varatharajalu Udayasuriyan 2, Vijaipal Bhadana 3

Affiliations + expand

PMID: 34822069 PMCID: PMC8613526 DOI: 10.1007/s11033-021-06749-4

Free PMC article

Abstract

Codon usage bias is the preferential or non-random use of synonymous codons, a ubiquitous phenomenon observed in bacteria, plants and animals. Different species have consistent and characteristic codon biases. Codon bias varies not only with species, family or group within kingdom, but also between the genes within an organism. Codon usage bias has evolved through mutation, natural selection, and genetic drift in various organisms. Genome composition, GC content, expression level and length of genes, position and context of codons in the genes, recombination rates, mRNA folding, and tRNA abundance and interactions are some factors influencing codon bias. The factors shaping codon bias may also be involved in evolution of the universal genetic code. Codon-usage bias is critical factor determining gene expression and cellular function by immericing diverse processes such as RNA processing, protein translation and protein folding. Codon usage bias reflects the origin, nutation patterns and evolution of the species or genes. Investigation of the species of genes, horizontal gene transfers, molecular evolution of genes and identify selective

Caption





Codon usage bias

Sujatha Thankeswaran Parvathy 1, Varatharajalu Udayasuriyan 2, Vijaipal Bhadana 3

Affiliations + expand

PMID: 34822069 PMCID: PMC8613526 DOI: 10.1007/s11033-021-06749-4

Free PMC article

Abstract

Codon usage bias is the preferential or non-random use of synonymous codons, a ubiquitous

phenomenon observed in bacteria, plants and animals. Differ characteristic codon biases. Codon bias varies not only with kingdom, but also between the genes within an organism. Comutation, natural selection, and genetic drift in various organism, expression level and length of genes, position and recombination rates, mRNA folding, and tRNA abundance are influencing codon bias. The factors shaping codon bias may

In summary, results derived from our evolutionary analysis suggest that 2019-nCoV has most similar genetic information with bat coronovirus and has most similar codon usage bias with snake. Additionally, a homologous recombination may occured


universal genetic code. Codon-usage bias is critical factor determining gene expression and cellular function by innucricing diverse processes such as RNA processing, protein translation and protein folding. Codon usage bias reflects the origin, nutation patterns and evolution of the species or genes. Investigations of codon bias patterns in good ones can reveal phylogenetic relationships

between organisms, horizontal gene transfers, molecular evolution of genes and identify selective



Caption









Snakes could be the source of the Wuhan coronavirus outbreak



By Haitao Guo, Guangxiang "George" Luo and Shou-Jiang Gao, The Conversation Updated 3:41 PM EST, Fri January 24, 2020









Snakes could be the source of the Wuhan coronavirus outbreak











What do you need to know about coronavirus?



Hear Rugby coach give motivational French speech in the...




Couple's former daughter-in-law suspected in...




(CNN) — Snakes - the Chinese krait and the Chinese cobra - may be the original source of the newly discovered coronavirus that has triggered an outbreak of a deadly infectious respiratory illness in China this winter.

The many-banded krait (Bungarus multicinctus), also known as the Taiwanese krait or the Chinese krait, is a highly venomous species of elapid snake found in much of central and southern China and Southeast Asia.



4/2020: France Researchers Isolate The 'Spike Protein Gene' of COVID-19 Virus & Publish, It's

Identical to 3 Things










Figure 1.

Nicotine may be suggested as a potential preventive agent against Covid-19 infection. Both the epidemiological/clinical evidence and the in silico findings may suggest that Covid-19 infection is a nAChR disease that could be prevented and may be controlled by nicotine. Nicotine would then sterically or allosterically compete with the SARS-CoV-2 binding to the nAChR. This legitimates the use of nicotine as a protective agent against SARS-CoV-2 infection and the subsequent deficits it causes in the CNS. Thus, in order to prevent the infection and the retro-propagation of the virus through the CNS, we plan a therapeutic assay against Covid-19 with nicotine (and other nicotinic agents) patches or other delivery methods (like sniffing/chewing) in hospitalized patients and in the general population.

In conclusion, we propose, and try to justify, the hypothesis that nAChRs play a critical role in the pathophysiology of SARS-CoV-2 infection and as a consequence propose nicotine and nicotinic orthosteric and/or allosteric agents as





```
COBRA TOXIN

RABV G (CVS)

RABV G (ERA)

RABV G (Mod. ERA)

BUNGAROTOXIN

SARS-COV-2 S

CD G F C S S . RGKR

RGKR-199

CD I F T N S . RGKR

CD I F T N S . RGKR

CD I F T N S . RGKR

CD A F C S S . RGKV

RGKR

RGKR

RGKR

CD A F C S S . RGKV

RGKR

RGKR


RABV G (Mod. ERA)

CD A F C S S . RGKV

RGKR

CD A F C S S . RGKV
```

Figure 1.







```
COBRA TOXIN

RABV G (CVS)

RABV G (ERA)

RABV G (Mod. ERA)

BUNGAROTOXIN

SARS-COV-2 S

CD G F C S S . RGKR

RGKR-199

CD I F T N S . RGKR

CD I F T N S . RGKR

CD I F T N S . RGKR

CD A F C S S . RGKV

RGKR

RGKR


RGKR

CD A F C S S . RGKV

RGKR

PRRAR-685
```

Figure 1.







Nicotine may be suggested as a potential preventive agent against Covid-19 infection. Both the epidemiological/clinical evidence and the in silico findings may suggest that Covid-19 infection is a nAChR disease that could be prevented and may be controlled by nicotine. Nicotine would then sterically or allosterically compete with the SARS-CoV-2 binding to the nAChR. This legitimates the use of nicotine as a protective agent against SARS-CoV-2 infection and the subsequent deficits it causes in the CNS. Thus, in order to prevent the infection and the retro-propagation of the virus through the CNS, we plan a therapeutic assay against Covid-19 with nicotine (and other nicotinic agents) patches or other delivery methods (like sniffing/chewing) in hospitalized patients and in the general population.

In conclusion, we propose, and try to justify, the hypothesis that nAChRs play a critical role in the pathophysiology of SARS-CoV-2 infection and as a consequence propose nicotine and nicotinic orthosteric and/or allosteric agents as a possible therapy for SARS-CoV-2 infection. Interestingly, ivermectin, which has been recently shown to inhibit the replication of SARS-CoV-2 in cells in vitro [53], is a positive allosteric modulator of α7 nAChR [54]. The nicotinic hypothesis might be further challenged by additional clinical studies and by experimental observations determining whether SARS-CoV-2 physically interacts with the nAChR in vitro, for instance by electrophysiological recordings, high resolution EM and by animal model studies. Further work should also specify





5/2023: NIH Published this Paper!





5/2023: NIH Published this Paper!





SARS-CoV-2 spike ectodomain targets a7 nicotinic acetylcholine receptors

Brittany C.V. O'Brien • Lahra Weber • Karsten Hueffer • Maegan M. Weltzin 🔌 🖂

Open Access • DOI: https://doi.org/10.1016/j.jbc.2023.104707 •



Keywords

Results

Discussion

Experimental procedures

Data availability

Supporting information

Conflict of interest

Acknowledgments

Virus entry into animal cells is initiated by attachment to target macromolecules located on host cells. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike glycoprotein targets host angiotensin converting enzyme 2 to gain cellular access. The SARS-CoV-2 glycoprotein contains a neurotoxin-like region that has sequence similarities to the rabies virus and the HIV glycoproteins, as well as to snake neurotoxins, which interact with nicotinic acetylcholine receptor (nAChR) subtypes via this region. Using a peptide of the neurotoxin-like region of SARS-CoV-2 (SARS-CoV-2 glycoprotein peptide [SCoV2P]), we identified that this area moderately inhibits $\alpha 3\beta 2$, $\alpha 3\beta 4$, and $\alpha 4\beta 2$ subtypes, while potentiating and inhibiting $\alpha 7$ nAChRs. These nAChR subtypes





5/2023: NIH Published this Paper!





SARS-CoV-2 spike ectodomain targets a7 nicotinic acetylcholine receptors

Brittany C.V. O'Brien • Lahra Weber • Karsten Hueffer • Maegan M. Weltzin 🔌 🖂

Open Access • DOI: https://doi.org/10.1016/j.jbc.2023.104707 •



Keywords

Results

Discussion

Experimental procedures

Data availability

Supporting information

Conflict of interest

Acknowledgments

Virus entry into animal cells is initiated by attachment to target macromolecules located on host cells. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike glycoprotein targets host angiotensin converting enzyme 2 to gain cellular access. The SARS-CoV-2 glycoprotein contains a neurotoxin-like region that has sequence similarities to the rabies virus and the HIV glycoproteins, as well as to snake neurotoxins, which interact with nicotinic acetylcholine receptor (nAChR) subtypes *via* this region. Using a peptide of the neurotoxin-like region of SARS-CoV-2 (SARS-CoV-2 glycoprotein peptide [SCoV2P]), we identified that this area moderately inhibits α3β2, α3β4, and α4β2 subtypes, while potentiating and inhibiting α7 nAChRs. These nAChR subtypes





COVID-19 Virus "Spike Protein...Contains Snake Neurotoxins & HIV Glycoprotein"...? DID YOU KNOW?





COVID-19 Virus "Spike Protein...Contains Snake Neurotoxins & HIV Glycoprotein"...? DID YOU

da Mata et al. Journal of Venomous Animals and Toxins including
Tropical Diseases (2017) 23:3
DOI 10.1186/s40409-016-0089-0

Journal of Venomous Animals and Toxins including Tropical Diseases

REVIEW Open Access

Antiviral activity of animal venom peptides and related compounds



Élida Cleyse Gomes da Mata¹, Caroline Barbosa Farias Mourão¹, Marisa Rangel^{1,2} and Elisabeth Ferroni Schwartz^{1*}

Abstract

Viruses exhibit rapid mutational capacity to trick and infect host cells, sometimes assisted through virus-coded peptides that counteract host cellular immune defense. Although a large number of compounds have been identified as inhibiting various viral infections and disease progression, it is urgent to achieve the discovery of more effective agents. Furthermore, proportionally to the great variety of diseases caused by viruses, very few viral vaccines are available, and not all are efficient. Thus, new antiviral substances obtained from natural products have been prospected, including those derived from venomous animals. Venoms are complex mixtures of hundreds of molecules, mostly peptides, that present a large array of biological activities and evolved to putatively target the biochemical machinery of different pathogens or host cellular structures. In addition, non-venomous compounds, such as some body fluids of invertebrate organisms, exhibit antiviral activity. This review provides a panorama of peptides described from animal venoms that present antiviral activity, thereby reinforcing them as important tools for the development of new therapeutic drugs.

Keywords: Antiretroviral agents, Antiviral agents, HIV, Scorpion venom, Snake venom, Amphibian venom, Insect venom, Marine animal peptides





COVID-19 Virus "Spike Protein...Contains Snake Neurotoxins & HIV Glycoprotein"...? DID YOU

KNOW?

Snake venoms

Snake venoms are composed of a mixture of proteins, peptides (90-95%), free amino acids, nucleotides, lipids, carbohydrates and metallic elements coupled to proteins (5%) [45]. Some studies have reported the antiviral activity of snake venoms and their components against measles virus, Sendai virus, dengue virus (DENV), yellow fever virus (YFV) and HIV [46-50]. Thus, snake venoms are sources of promising candidates for new antiviral drugs (Table 2). In relation to antiretroviral activity, the benefits of treating a patient with multidrug-resistant HIV with a snake venom preparation in addition to the antiretroviral therapy were demonstrated in clinical practice [51]. The response was a decreased viral load and elevated T CD4⁺cell count. The authors suggest that this activity may be related to the presence of some snake venom molecules that are homologous to HIV-1 glycoprotein or proteases [51, 52].





Neurotoxins & HIV Glycoprotein"...? DID YOU KNOW?

What does "Homologous" Mean?

Snake venoms

Snake venoms are composed of a mixture of proteins, peptides (90-95%), free amino acids, nucleotides, lipids, carbohydrates and metallic elements coupled to proteins (5%) [45]. Some studies have reported the antiviral activity of snake venoms and their components against measles virus, Sendai virus, dengue virus (DENV), yellow fever virus (YFV) and HIV [46-50]. Thus, snake venoms are sources of promising candidates for new antiviral drugs (Table 2). In relation to antiretroviral activity, the benefits of treating a patient with multidrug-resistant HIV with a snake venom preparation in addition to the antiretroviral therapy were demonstrated in clinical practice [51]. The response was a decreased viral load and elevated T CD4⁺cell count. The authors suggest that this activity may be related to the presence of some snake venom molecules that are homologous to HIV-1 glycoprotein or proteases [51, 52].





COVID-19 Virus "Spike Protein...Contains Snake Neurotoxins & HIV Glycoprotein"...? DID YOU

homologous

Synonyms of homologous >

What does
"Homologous" Mean?



homologous adjective

ho·mol·o·gous (hō-'mä-lə-gəs ◄)) hə

- 1 a: having the same relative position, value, or structure: such as
 - (1) biology: exhibiting biological homology
 - (2) **biology**: having the same or allelic genes with genetic loci usually arranged in the same order

Q

Games & Quizzes

homologous chromosomes

- **b chemistry** : belonging to or consisting of a chemical series (see SERIES sense 6) whose successive members have a regular difference in composition especially of one methylene group
- **2 biology** : derived from or developed in response to organisms of the same species





Word of the Day

Neurotoxins & HIV Glycoprotein"...? DID YOU KNOW?

What does "Homologous" Mean?

"DERIVED FROM"

Snake venoms

Snake venoms are composed of a mixture of proteins, peptides (90-95%), free amino acids, nucleotides, lipids, carbohydrates and metallic elements coupled to proteins (5%) [45]. Some studies have reported the antiviral activity of snake venoms and their components against measles virus, Sendai virus, dengue virus (DENV), yellow fever virus (YFV) and HIV [46-50]. Thus, snake venoms are sources of promising candidates for new antiviral drugs (Table 2). In relation to antiretroviral activity, the benefits of treating a patient with multidrug-resistant HIV with a snake venom preparation in addition to the antiretroviral therapy were demonstrated in clinical practice [51]. The response was a decreased viral load and elevated T CD4⁺cell count. The authors suggest that this activity may be related to the presence of some snake venom molecules that are homologous to HIV-1 glycoprotein or proteases [51, 52].





Neurotoxins & HIV Glycoprotein"...? DID YOU KNOW?

What does "Homologous" Mean?

"DERIVED FROM"

Snake venoms

Snake venoms are composed of a mixture of proteins, peptides (90-95%), free amino acids, nucleotides, lipids, carbohydrates and metallic elements coupled to proteins (5%) [45]. Some studies have reported the antiviral activity of snake venoms and their components against measles virus, Sendai virus, dengue virus (DENV), yellow fever virus (YFV) and HIV [46-50]. Thus, snake venoms are sources of promising candidates for new antiviral drugs (Table 2). In relation to antiretroviral activity, the benefits of treating a patient with multidrug-resistant HIV with a snake venom preparation in addition to the antiretroviral therapy were demonstrated in clinical practice [51]. The response was a decreased viral load and elevated T CD4⁺cell count. The authors suggest that this activity may be related to the presence of some snake venom molecules that are homologous to HIV-1 glycoprotein or proteases [51, 52].

Thus: HIV-1 Glycoprotein is

"DERIVED FROM"

SNAKE VENOM!







OPEN BACCESS

SARS-CoV-2 spike ectodomain targets a7 nicotinic acetylcholine receptors

Brittany C.V. O'Brien • Lahra Weber • Karsten Hueffer • Maegan M. Weltzin 😕 🖂

Open Access • DOI: https://doi.org/10.1016/j.jbc.2023.104707 •



Keywords

Results

Discussion

Experimental procedures

Data availability

Supporting information

Conflict of interest

Acknowledgments

Virus entry into animal cells is initiated by attachment to target macromolecules located on host cells. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike glycoprotein targets host angiotensin converting enzyme 2 to gain cellular access. The SARS-CoV-2 glycoprotein contains a neurotoxin-like region that has sequence similarities to the rabies virus and the HIV glycoproteins, as well as to snake neurotoxins, which interact with nicotinic acetylcholine receptor (nAChR) subtypes via this region. Using a peptide of the neurotoxin-like region of SARS-CoV-2 (SARS-CoV-2 glycoprotein peptide [SCoV2P]), we identified that this area moderately inhibits $\alpha 3\beta 2$, $\alpha 3\beta 4$, and $\alpha 4\beta 2$ subtypes, while potentiating and inhibiting $\alpha 7$ nAChRs. These nAChR subtypes







Contents lists available at ScienceDirect

Heliyon

journal homepage: www.cell.com/heliyon



Review article

Interactions between the rabies virus and nicotinic acetylcholine receptors: A potential role in rabies virus induced behavior modifications



Marianne Lian a,b,1, Karsten Hueffer a, Maegan M. Weltzin c,*

https://www.cell.com/heliyon/fulltext/S2405-8440(22)01722-





^a University of Alaska Fairbanks, Department of Veterinary Medicine, 2141 Koyukuk Drive, Fairbanks, AK, 99775, USA

^b Inland Norway University of Applied Sciences, Department of Forestry and Wildlife Management, Koppang, NO-2480, Norway

^c University of Alaska Fairbanks, Department of Chemistry and Biochemistry, 1930 Yukon Dr. Fairbanks, AK, 99775, USA

Highlights

- Rabies virus glycoprotein ectodomain binds to nAChRs.
- Glycoprotein and nAChR-selective α-neurotoxins share regions of sequence homology.
- Peptide of the rabies virus glycoprotein modifies behavior in mice.
- Nicotine and genetic deletion of α7 nAChRs modulates pathological aggression.
- We hypothesize rabies virus glycoprotein-nAChR interactions modulate behavior.

https://www.cell.com/heliyon/fulltext/S2405-8440(22)01722-





Highlights

- Rabies virus glycoprotein ectodomain binds to nAChRs.
- Glycoprotein and nAChR-selective α-neurotoxins share regions of sequence homology.
- Peptide of the rabies virus glycoprotein modifies behavior in mice.
- Nicotine and genetic deletion of α7 nAChRs modulates pathological aggression.
- We hypothesize rabies virus glycoprotein-nAChR interactions modulate behavior.

https://www.cell.com/heliyon/fulltext/S2405-8440(22)01/22-





5. RGP binds to nAChRs via a neurotoxin-like domain

The RGP contains a neurotoxin-like region which shows a significant sequence homology with snake α -neurotoxins that function as potent nAChR subtype selective antagonists [62, 63]. Several lines of evidence have identified the α 1 nAChR subunit to contain the RGP binding site, which overlaps with the α -bungarotoxin site. nAChR α 1 subunit mono-

cultured muscles cells with a high density of nAChRs [38]. RABV binding to the muscle-type nAChR was inhibited by nAChR antagonists, up to 50% by α -bungarotoxin and up to 30% by (+)-tubocurarine, but binding was not affected by the muscarinic acetylcholine receptor antagonist atropine [64]. Later, the RABV was confirmed to bind to the *Torpedo*

https://www.cell.com/heliyon/fulltext/S2405-8440(22)01722-





5. RGP binds to nAChRs via a neurotoxin-like domain

The RGP contains a neurotoxin-like region which shows a significant sequence homology with snake α -neurotoxins that function as potent nAChR subtype selective antagonists [62, 63]. Several lines of evidence have identified the α 1 nAChR subunit to contain the RGP binding site, which overlaps with the α -bungarotoxin site. nAChR α 1 subunit mono-

cultured muscles cells with a high density of nAChRs [38]. RABV binding to the muscle-type nAChR was inhibited by nAChR antagonists, up to 50% by α -bungarotoxin and up to 30% by (+)-tubocurarine, but binding was not affected by the muscarinic acetylcholine receptor antagonist atropine [64]. Later, the RABV was confirmed to bind to the *Torpedo*

https://www.cell.com/heliyon/fulltext/S2405-8440(22)01722-





5. RGP binds to nAChRs via a neurotoxin-like domain

The RGP contains a neurotoxin-like region which shows a significant sequence homology with snake α -neurotoxins that function as potent nAChR subtype selective antagonists [62, 63]. Several lines of evidence have identified the α 1 nAChR subunit to contain the RGP binding site, which overlaps with the α -bungarotoxin site. nAChR α 1 subunit mono-

cultured muscles cells with a high density of nAChRs [38]. RABV binding to the muscle-type nAChR was inhibited by nAChR antagonists, up to 50% by α -bungarotoxin and up to 30% by (+)-tubocurarine, but binding was not affected by the muscarinic acetylcholine receptor antagonist atropine [64]. Later, the RABV was confirmed to bind to the *Torpedo*

https://www.cell.com/heliyon/fulltext/S2405-8440(22)01722-





Loop II of α -bungarotoxin and α -cobratoxin have approximately 50% sequence homology to the RGP neurotoxin-like domain (Table 1). Cir-

https://www.cell.com/heliyon/fulltext/S2405-8440(22)01722-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2405844022017224%3Fshowall%3Dtrue





Loop II of α -bungarotoxin and α -cobratoxin have approximately 50% sequence homology to the RGP neurotoxin-like domain (Table 1). Cir-

mostly of beta sheet structure [70]. This study showed that a peptide of the RGP neurotoxin domain is structurally similar to loop II of α -neurotoxins. Using a Asn194-Ser195-Arg196-Gly197 tetrapeptide, early mo-

https://www.cell.com/heliyon/fulltext/S2405-8440(22)01722-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2405844022017224%3Fshowall%3Dtrue





Nicotinic Acetylcholine Receptors in HIV: Possible Roles During HAND and Inflammation

Coral M. Capó-Vélez^{1,2} · Manuel Delgado-Vélez^{1,2} · Carlos A. Báez-Pagán^{1,3} · José A. Lasalde-Dominicci^{1,2}

Received: 31 January 2018 / Accepted: 9 July 2018 / Published online: 14 July 2018 © The Author(s) 2018

Abstract

Infection with the human immunodeficiency virus (HIV) remains a threat to global health. Since its discovery, many efforts have been directed at understanding the mechanisms and consequences of infection. Although there have been substantial advances since the advent of antiretroviral therapy, there are still complications that significantly compromise the health of infected patients, particularly, chronic inflammation and HIV-associated neurocognitive disorders (HAND). In this review, a new perspective is addressed in the field of HIV, where the alpha7 nicotinic acetylcholine receptor (α 7-nAChR) is the protagonist. We comprehensively discuss the available evidence implicating α 7-nAChRs in the context of HIV and provide possible explanations about its role in HAND and inflammation in both the central nervous system and the periphery.

Keywords Nicotinic acetylcholine receptor · HIV · Gp120 · Inflammation · HAND





Besides AIDS, HIV infection results in a series of systematic physiological complications such as chronic inflammation and HIV-associated neurocognitive disorders (HAND),





particular, the α 7-nAChR is emerging as an important player in the HIV field, since it is expressed not only in the brain, but also in a wide variety of immune cells that are targeted during HIV infection, such as macrophages, monocytes, B-lymphocytes, and T-lymphocytes (CD4⁺) (Wang et al. 2003; van der Zanden et al. 2012; Kawashima et al. 2015), making it a suitable target for treatment development.





Studies performed by Bracci et al. demonstrated a significant homology between a specific sequence of gp120, the coat protein of HIV, and the putative active sites of snake curare-mimetic neurotoxins, which have the ability to bind irreversibly to nAChRs. Furthermore, the authors demonstrated that recombinant gp120 inhibits the binding of the nAChR antagonist, α -bgtx, suggesting that other type of receptors (such as nAChRs) can function as HIV receptors, and supports the notion that ion channels may have a role during HIV infection. Even though this study





Studies performed by Bracci et al. demonstrated a significant homology between a specific sequence of gp120, the coat protein of HIV, and the putative active sites of snake curare-mimetic neurotoxins, which have the ability to bind irreversibly to nAChRs. Furthermore, the authors demonstrated that recombinant gp120 inhibits the binding of the nAChR antagonist, α -bgtx, suggesting that other type of receptors (such as nAChRs) can function as HIV receptors, and supports the notion that ion channels may have a role during HIV infection. Even though this study





HYPOTHESIS Open Access



Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?



Abstract

https://bioelecmed.biomedcentral.com/articles/10.1186/s42234-023-00104-7





Following a SARS-CoV-2 infection, many individuals suffer from post-COVID-19 syndrome. It makes them unable to proceed with common everyday activities due to weakness, memory lapses, pain, dyspnea and other unspecific physical complaints. Several investigators could demonstrate that the SARS-CoV-2 related spike glycoprotein (SGP) attaches not only to ACE-2 receptors but also shows DNA sections highly affine to nicotinic acetylcholine receptors (nAChRs). The nAChR is the principal structure of cholinergic neuromodulation and is responsible for coordinated neuronal network interaction. Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh). We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days.

Keywords Post COVID 19 syndrome, Cholinergic neuromodulation, Nicotine, Nicotinic acetylcholine receptors, Vagus nerve signaling

Introduction

Post-COVID-19-syndrome

which ultimately helped to create sufficiently protective vaccines. The pathogen, however, always seems to be one









Following a SARS-CoV-2 infection, many individuals suffer from post-COVID-19 syndrome. It makes them unable to proceed with common everyday activities due to weakness, memory lapses, pain, dyspnea and other unspecific physical complaints. Several investigators could demonstrate that the SARS-CoV-2 related spike glycoprotein (SGP) attaches not only to ACE-2 receptors but also shows DNA sections highly affine to nicotinic acetylcholine receptors (nAChRs). The nAChR is the principal structure of cholinergic neuromodulation and is responsible for coordinated neuronal network interaction. Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh). We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days.







Following a SARS-CoV-2 infection, many individuals suffer from post-COVID-19 syndrome. It makes them unable to proceed with common everyday activities due to weakness, memory lapses, pain, dyspnea and other unspecific physical complaints. Several investigators could demonstrate that the SARS-CoV-2 related spike glycoprotein (SGP) attaches not only to ACE-2 receptors but also shows DNA sections highly affine to nicotinic acetylcholine receptors (nAChRs). The nAChR is the principal structure of cholinergic neuromodulation and is responsible for coordinated neuronal network interaction. Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh). We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days.





Following a SARS-CoV-2 infection, many individuals suffer from post-COVID-19 syndrome. It makes them unable to proceed with common everyday activities due to weakness, memory lapses, pain, dyspnea and other unspecific physical complaints. Several investigators could demonstrate that the SARS-CoV-2 related spike glycoprotein (SGP) attaches not only to ACE-2 receptors but also shows DNA sections highly affine to nicotinic acetylcholine receptors (nAChRs). The nAChR is the principal structure of cholinergic neuromodulation and is responsible for coordinated neuronal network interaction. Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh). We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days.







Following a SARS-CoV-2 infection, many individuals suffer from post-COVID-19 syndrome. It makes them unable to proceed with common everyday activities due to weakness, memory lapses, pain, dyspnea and other unspecific physical complaints. Several investigators could demonstrate that the SARS-CoV-2 related spike glycoprotein (SGP) attaches not only to ACE-2 receptors but also shows DNA sections highly affine to nicotinic acetylcholine receptors (nAChRs). The nAChR is the principal structure of cholinergic neuromodulation and is responsible for coordinated neuronal network interaction. Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh). We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days.





more infected patients recovering from the acute phase of COVID-19 along with a large population needing therapy and rehab capacity (Stam et al. 2020; Barker-Davies et al. 2020; Klitzman 2020) to cure the symptoms of the chronic phase (Barker-Davies et al. 2020), better known as post-COVID-19-syndrome (Nath 2020).

Is it just the ACE2 receptor?

For the acute infection phase, physicians are lacking a causal therapeutic strategy to challenge the viral assault on human organ systems and must confine themselves to symptomatic therapeutic approaches for their patients. In severe cases of SARS-CoV-2 infections, these options prove rather underwhelming (Iyer et al. 2020; Jeong et al. 2020), while the therapeutic situation remains vague regarding post-COVID-19 syndrome (Rimmer, 2020;

particles competing with acetylcholine for nAChR binding in order to enter the human body may lead to primary neuro infection (Changeux et al. 2020; Steardo et al. 2020). Furthermore, among the severe and fatal cases of COVID-19, the proportion of nicotine consumers was significantly lower than non-consumers of nicotine (Miyara, et al. 2020). Since nicotine may protect nAChRs from viral attachment, therapeutic nicotine application was proposed in the management of acute COVID-19 infections (Changeux et al. 2020). This argument is convincingly supported by the cohort study of Hippisley-Cox et al. (2020), with a total of 8.28 million participants (including 19,486 confirmed COVID-19 cases), showing lower odds for COVID-19 infection and COVID-19-related ICU stay in association with smoking (Hippisley-Cox et al. 2020).





more infected patients recovering from the acute phase of COVID-19 along with a large population needing therapy and rehab capacity (Stam et al. 2020; Barker-Davies et al. 2020; Klitzman 2020) to cure the symptoms of the chronic phase (Barker-Davies et al. 2020), better known as post-COVID-19-syndrome (Nath 2020).

Is it just the ACE2 receptor?

For the acute infection phase, physicians are lacking a causal therapeutic strategy to challenge the viral assault on human organ systems and must confine themselves to symptomatic therapeutic approaches for their patients. In severe cases of SARS-CoV-2 infections, these options prove rather underwhelming (Iyer et al. 2020; Jeong et al. 2020), while the therapeutic situation remains vague regarding post-COVID-19 syndrome (Rimmer, 2020; particles competing with acetylcholine for nAChR binding in order to enter the human body may lead to primary neuro infection (Changeux et al. 2020; Steardo et al. 2020). Furthermore, among the severe and fatal cases of COVID-19, the proportion of nicotine consumers was significantly lower than non-consumers of nicotine (Miyara, et al. 2020). Since nicotine may protect nAChRs from viral attachment, therapeutic nicotine application was proposed in the management of acute COVID-19 infections (Changeux et al. 2020). This argument is convincingly supported by the cohort study of Hippisley-Cox et al. (2020), with a total of 8.28 million participants (including 19,486 confirmed COVID-19 cases), showing lower odds for COVID-19 infection and COVID-19-related ICU stay in association with smoking (Hippisley-Cox et al. 2020).





Farsalinos et al. (2020) examined and identified a "toxin-like" aa sequence in the receptor binding domain of the SARS-CoV-2 spike glycoprotein (SGP) (aa 375-390) which shows significant sequence homology with the neurotoxin homolog NL1, one of the many snake venom toxins interacting with nAChRs (Farsalinos, et al. 2020). Additionally, they performed computa-





Farsalinos et al. (2020) examined and identified a "toxin-like" aa sequence in the receptor binding domain of the SARS-CoV-2 spike glycoprotein (SGP) (aa 375-390) which shows significant sequence homology with the neurotoxin homolog NL1, one of the many snake venom toxins interacting with nAChRs (Farsalinos, et al. 2020). Additionally, they performed computa-





Farsalinos et al. (2020) examined and identified a "toxin-like" aa sequence in the receptor binding domain of the SARS-CoV-2 spike glycoprotein (SGP) (aa 375-390) which shows significant sequence homology with the neurotoxin homolog NL1, one of the many snake venom toxins interacting with nAChRs (Farsalinos, et al. 2020). Additionally, they performed computa-





"Profound similarities between...toxins (found in the venom of)...snakes of the Ophiophagus (king cobra) and Bungarus (krait snake)...and SARS-CoV-2 (spike) proteins...were found... (Farsalinos et al. 2020; Changeux et al. 2020)."

Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orches... 3 / 15 | - 175% +



Our group recently described the crucial relevance of autonomic balance for the severity of COVID-19 disease courses (Leitzke et al. 2020; Leitzke and Schönknecht 2021) and highlighted the significance of nicotinic acetylcholine receptors (nAChRs) for the limiting regulation of cytokine liberation and virus replication on the transcriptional level, restricting NF-KB action along the cholinergic anti-inflammatory pathway (CAP) (Leitzke et al. 2020; Leitzke and Schönknecht 2021). Profound similarities between highly nAChR affine toxins (i.e., from snakes of the Ophiophagus (cobra) and Bungarus genera, the G-ectodomains of three Rabies lyssavirus (formerly Rabies virus) (RABV) strains (Changeux et al. 2020) or muscarinic toxin-like protein and Cobratoxin (naja siamensis) (Farsalinos et al. 2020)) and SARS-CoV-2 specific proteins (Farsalinos et al. 2020; Changeux et al. 2020) were found by analyzing the toxin's amino-acid (aa) sequence alignment and comparing it to the motifs in spike glycoprotein (SGP) from SARS-CoV-2 (Farsalinos et al. 2020; Changeux et al. 2020).

of the extracellular domain of the nAChR α9 subunit (Farsalinos, et al. 2020), the core of the "toxin-binding site" of nAChRs (Farsalinos, et al. 2020). Likewise, a similar interaction could be demonstrated between the ligand binding domain of the pentameric α7 nicotinic acetylcholine receptor (α7nAChR) chimera and the SARS-CoV-2 SGP (Farsalinos, et al. 2020). The authors concluded that their findings strongly support the hypothesis of a dysregulation in the nicotinic cholinergic system being a considerable part of COVID-19's pathophysiology (Farsalinos, et al. 2020).

The pivotal neuromodulation role of nicotinic acetylcholine receptors

Within the central nervous system (CNS), acetylcholine (ACh) is released mainly from projection neurons (PN), which innervate distal areas, and local interneurons interspersing their cellular targets. PNs are found in several nuclei, including the medial habenula, pedunculopontine and laterodorsal tegmental areas, as well





Material

We investigated one female (32 years old) and 3 males (19, 41 and 52 years old, respectively) who suffered from numerous symptoms indicative of post-COVID-19 syndrome following a PCR-confirmed SARS-CoV-2 infection with a subsequent mild course of disease. The patients described weakness, dyspnea, sleep disturbances, dizziness, complete ageusia and anosmia, along with a variety of other symptoms. Except for the youngest, the patients






Methods

After meticulously explaining the hypothesis described above, as well as the expected effects of nicotine and possible side effects, the patients were advised to apply a standard nicotine patch. Since all included individuals were nicotine-naïve persons, they were instructed to use the lowest available dosage (7.5 mg/24 h) and to administer the patch once daily (in the morning). All patients
































Discussion

Each of the four presented cases showed significant alleviation of their persistent symptoms; improvement was reached either immediately following nicotine patch application or in rapid succession after treatment began. There were clear differences in the patterns and the time spans for symptom relief among the four cases. It is also worth noting that the course of symptom improvement in each of the presented cases was independent of their drastically different lengths and progression prior to nicotine therapy.





In each case, signs of exhaustion such as fatigue, weakness, breathlessness and exercise intolerance improved rapidly and across the board following nicotine exposure (at the very latest by day six). In cases with impairment or loss of the senses of taste and smell, improvement was observed over a longer period, with complete restoration of these senses over anywhere from thirteen to sixteen days.





The release of the SARS-CoV-2 virus from nAChR receptors can lead to short-term viremia with signs of acute SARS-CoV-2 infection when starting nicotine therapy; however, this viral load should be neutralized within a short period of time by the humoral component of the immune system due to SARS-CoV-2 antibodies formed during the acute phase of infection (Fig. 2C,D).





The Published Conclusion of this Study!

option more closely seem feasible. Based on the results of this case study, this treatment option—using nicotine patches to combat long-haul COVID—seems far superior to the time-consuming, often underwhelming or disappointing, costly and complex rehabilitation measures currently available to these patients.





Will I Become Addicted To Nicotine Patches?

Transcutaneous administration of nicotine ensures constant serum levels without relevant peak levels. Thus, we did not see any development of nicotine dependence in the context of nicotine patch therapy. From the author's point of view, this is not to be expected.

https://bioelecmed.biomedcentral.com/articles/10.1186/s42234-023-00104-7





"Ask Your Doctor if 7mg NICOTINE PATCHES Are Right For You?"

















NEW LIQUID FORMULATION

EDTA NOW EVEN BETTER!

- ✓ Calcium Disodium EDTA
- **☑** Better Absorption
- More Bioavailable
- Advanced Glycerosomal Technology
- Powerful Protection

20% OFF SALE!

Use code REAWAKEN at checkout.

Offer applies to EDTA, Foregin Protein Cleanse, Cardio Flow, Docs Viral Defense and Propolis Throat Sprays. Offer ends at midnight 10/18/23



Scan QR and watch Dr Ardis video on EDTA to learn more!





NEW PRODUCT

FOREIGN PROTEIN CLEANSE

- **☑** Detox Spike Proteins
- Rapid Delivery Liquid Formulation
- **☑** Enhanced Bioavailability
- Cold-Processed Acoustic
 BioSomal Technology™
- Potent Cleansing Formula
- **☑** Enhance Immunity



GET 20% OFF! Use code REAWAKEN at checkout. Scan QR to watch video!

Offer applies to EDTA, Foregin Protein Cleanse, Cardio Flow, Doc'S Viral Defense and Propolis Throat Sprays. Offer ends at midnight 10/18/23







HEALING FOR THE A.G.E.S.

GROUP SCHMIDT



GET DIGITAL **ACCESS NOW**

\$50 OFF

You'll get access to all the session recordings, Q&A's & downloadable supporting assets.

AT CHECKOUT USE PROMOCODE: ARDIS

https://www.healingfortheages.com

